BELFOR
22.6.2022 17:39:12 CEST | Business Wire | Pressemeddelelse
BELFOR, verdens største skadeservicevirksomhed og SSG, førende på det skandinaviske marked inden for skadesanering og genopbygning, har slået sig sammen for at styrke vores kundeservice i Danmark, Norge og Sverige.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220622005634/da/
BELFOR har nu mere end 12.500 medarbejdere og 500+ lokationer i hele verden. Vi dækker alle led, når det kommer til genopbygning efter en skade. Vi vurderer skaden, igangsætter nødvendige foranstaltninger, og vi sørger for renovering og genopbygning, uanset skadens omfang.
SSG Group tilbyder bl.a. skadeservice, renovering og genopbygning og har 980 medarbejdere, fordelt på 57 lokationer i Danmark, Sverige og Norge.
"Med SSG udvider vi vores dygtige og erfarne teams med gode folk, øger vores servicekapacitet og optimerer vores responstider for vores nationale og internationale kunder", udtaler Elvir Kolak, CEO for BELFOR Europe.
"Denne transaktion betyder et enormt løft for vores organisationer i Danmark, Norge og Sverige. Ved at kombinere BELFORS tekniske kompetencer med vores serviceportefølje åbner vi for nye udviklingsmuligheder for vores medarbejdere", tilføjer Carsten Fensholt, CEO for SSG Group.
"Vi er glade for at byde SSG velkommen i BELFOR-familien, og vi glæder os til at medvirke til deres fremtidige vækst. SSG beskæftiger fantastiske medarbejdere og har stort fokus på kunderne – og er derfor et perfekt match for os! Vi er stolte over at få dem ombord. Hos BELFOR er vores vækstplaner ambitiøse, og vi leder aktivt efter gode virksomheder, der kan tilslutte sig BELFOR-familien – både i Skandinavien og resten af Europa", afslutter Sheldon Yellen, global CEO hos BELFOR.
Fremover vil BELFOR være Danmarks førende skadeservicevirksomhed med tilføjelsen af 650 nye medarbejdere. Opkøbet af SSG er et stort skridt på vejen mod en større tilstedeværelse i Skandinavien, som startede med erhvervelsen af det danske skadeservicefirma, Røsva, efterfulgt af Rølund i 2021.
OM BELFOR
BELFOR er førende på det globale marked inden for skadeservice. Med mere end 40 års erfaring kan vi hos BELFOR tilbyde at hjælpe dig igennem hele dit skadesforløb, lige fra vurdering af skaden, til renovering og genopbygning. Det betyder bl.a., at vi er den foretrukne partner både for forsikringsselskaber samt kommercielle og private kunder. Med SSG under fanen har BELFOR nu mere end 12.500 ansatte og 500 lokationer i 57 lande. Vi er klar til at hjælpe vores kunder 24 timer i døgnet, 365 dage om året, uanset hvor store og komplekse skaderne er.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220622005634/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum